|
| Status |
Public on Nov 22, 2019 |
| Title |
Sample9_598370: D00000000206095_WEEK 4_Tofacitinib |
| Sample type |
protein |
| |
|
| Source name |
Blood_WEEK 4_Tofacitinib
|
| Organism |
Homo sapiens |
| Characteristics |
visit: WEEK 4
treatment: CP-690,550 10 mg BID
treatmentshort: Tofacitinib
pasi: 4.3
pasi.baseline: 12.6
pasi.week4: 4.3
pasi.week12: 2.2
tag: 83
pasi75.response: R
age: 47
gender: F
platesimple: Plate3
plate: Plate3_CVD_A3921080_LOD
|
| Treatment protocol |
Patients were treated with either tofacitinib 10mg QD or etanercept 50mg BIW as described in ClinicalTrials.gov: NCT01241591 and Bachelez et al., 2015
|
| Extracted molecule |
protein |
| Extraction protocol |
see manufacture protocol https://www.olink.com/content/uploads/2017/11/0935-v1.9.4-Proseek-Multiplex-User-Manual_final.pdf
|
| Label |
oligonucleotide-labeled antibody
|
| Label protocol |
see manufacture protocol https://www.olink.com/content/uploads/2017/11/0935-v1.9.4-Proseek-Multiplex-User-Manual_final.pdf
|
| |
|
| Hybridization protocol |
see manufacture protocol https://www.olink.com/content/uploads/2017/11/0935-v1.9.4-Proseek-Multiplex-User-Manual_final.pdf
|
| Scan protocol |
Detection and quantification of the resulting DNA sequences was performed using microfluidic real-time quantitative PCR chip (96.96, Dynamic Array IFC, Fluidigm Biomark, South San Francisco, CA).
|
| Data processing |
Detection and quantification of the resulting DNA sequences was performed using microfluidic real-time quantitative PCR chip (96.96, Dynamic Array IFC, Fluidigm Biomark, South San Francisco, CA).
|
| |
|
| Submission date |
Aug 27, 2019 |
| Last update date |
Nov 22, 2019 |
| Contact name |
Lewis Elwood Tomalin |
| E-mail(s) |
l.tomalin1987@gmail.com
|
| Organization name |
Icahn School of Medicine at Mount Sinai
|
| Department |
Population Health Science & Policy
|
| Street address |
303 East 71st Street, Apt1B
|
| City |
New York |
| State/province |
New York |
| ZIP/Postal code |
10021 |
| Country |
USA |
| |
|
| Platform ID |
GPL27151 |
| Series (2) |
| GSE136431 |
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept (CVD data set) |
| GSE136435 |
Early quantification of systemic inflammatory (INF) and cardiovascular disease (CVD) proteins predicts long-term treatment response to Tofacitinib and Etanercept |
|
